Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $119

Barclays analyst Etzer Darout has maintained an Overweight rating on Protagonist Therapeutics (NASDAQ: PTGX) and increased the price target from $113 to $119. This adjustment reflects a positive outlook on the company's performance.